Impairment of the ABCA1 and SR-BI-mediated cholesterol efflux pathways and HDL anti-inflammatory activity in Alzheimer's disease

Mechanisms of Ageing and Development

Volumn 133, Issue 1, 2012, Pages 20-29

  Khalil, Abdelouahed ^a   Berrougui, Hicham ^a,b   Pawelec, Graham ^c   Fulop, Tamas ^a  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

^b SULTAN MOULAY SLIMANE UNIVERSITY   (Morocco)

^c UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

ABCA1; Alzheimer's disease; Anti inflammatory activity; Cholesterol efflux; HDL; SR BI

Indexed keywords

ABC TRANSPORTER A1; ALPHA TOCOPHEROL; APOLIPOPROTEIN A1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERCELLULAR ADHESION MOLECULE 1; MALONALDEHYDE; SCAVENGER RECEPTOR BI;

AGED; ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHOLESTEROL TRANSPORT; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ELECTROPHORETIC MOBILITY; FEMALE; HUMAN; HUMAN CELL; MACROPHAGE; MALE; MINI MENTAL STATE EXAMINATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LIPID INTERACTION; PROTEIN PURIFICATION; VITAMIN BLOOD LEVEL;

AGED; AGED, 80 AND OVER; ALPHA-TOCOPHEROL; ALZHEIMER DISEASE; APOLIPOPROTEIN A-I; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE; CHOLESTEROL, HDL; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; INTERCELLULAR ADHESION MOLECULE-1; MALE; MALONDIALDEHYDE; OXIDATIVE STRESS; SCAVENGER RECEPTORS, CLASS B;

EID: 84856235572     PISSN: 00476374     EISSN: 18726216     Source Type: Journal    
DOI: 10.1016/j.mad.2011.11.008     Document Type: Article

References (76)

1. Abad-Rodriguez J., Ledesma M.D., Craessaerts K., Perga S., Medina M., Delacourte A., Dingwall C., De Strooper B., Dotti C.G. Neuronal membrane cholesterol loss enhances amyloid peptide generation. The Journal of Cell Biology 2004, 167:953-960.
2. Agarwal R., Chase S.D. Rapid, fluorimetric-liquid chromatographic determination of malondialdehyde in biological samples. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences 2002, 775:121-126.
3. Aisen P.S., Davis K.L. Inflammatory mechanisms in Alzheimer's disease: implications for therapy. The American Journal of Psychiatry 1994, 151:1105-1113.
4. Arvanitakis Z., Wilson R.S., Bienias J.L., Evans D.A., Bennett D.A. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Archives of Neurology 2004, 61:661-666.
5. Attia N., Fournier N., Vedie B., Cambillau M., Beaune P., Ziegler O., Grynberg A., Paul J.L., Guerci B. Impact of android overweight or obesity and insulin resistance on basal and postprandial SR-BI and ABCA1-mediated serum cholesterol efflux capacities. Atherosclerosis 2010, 209:422-429.
6. Attie A.D., Kastelein J.P., Hayden M.R. Pivotal role of ABCA1 in reverse cholesterol transport influencing HDL levels and susceptibility to atherosclerosis. Journal of Lipid Research 2001, 42:1717-1726.
7. Balazs Z., Panzenboeck U., Hammer A., Sovic A., Quehenberger O., Malle E., Sattler W. Uptake and transport of high-density lipoprotein (HDL) and HDL-associated alpha-tocopherol by an in vitro blood-brain barrier model. Journal of Neurochemistry 2004, 89:939-950.
8. Baldan A., Bojanic D.D., Edwards P.A. The ABCs of sterol transport. Journal of Lipid Research 2009, 50(Suppl.):S80-S85.
9. Berrougui H., Isabelle M., Cloutier M., Grenier G., Khalil A. Age-related impairment of HDL-mediated cholesterol efflux. Journal of Lipid Research 2007, 48:328-336.
10. Bjorkhem I., Meaney S. Brain cholesterol: long secret life behind a barrier. Arteriosclerosis, Thrombosis, and Vascular Biology 2004, 24:806-815.
11. Bodovitz S., Klein W.L. Cholesterol modulates alpha-secretase cleavage of amyloid precursor protein. The Journal of Biological Chemistry 1996, 271:4436-4440.
12. Borggreve S.E., De Vries R., Dullaart R.P. Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transfer proteins. European Journal of Clinical Investigation 2003, 33:1051-1069.
13. Clark T.A., Lee H.P., Rolston R.K., Zhu X., Marlatt M.W., Castellani R.J., Nunomura A., Casadesus G., Smith M.A., Lee H.G., Perry G. Oxidative stress and its implications for future treatments and management of Alzheimer disease. International Journal of Biomedical Science: IJBS 2010, 6:225-227.
14. Cordy J.M., Hussain I., Dingwall C., Hooper N.M., Turner A.J. Exclusively targeting beta-secretase to lipid rafts by GPI-anchor addition up-regulates beta-site processing of the amyloid precursor protein. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:11735-11740.
15. Cuchel M., Rader D.J. Macrophage reverse cholesterol transport: key to the regression of atherosclerosis?. Circulation 2006, 113:2548-2555.
16. de la Llera-Moya M., Rothblat G.H., Connelly M.A., Kellner-Weibel G., Sakr S.W., Phillips M.C., Williams D.L. Scavenger receptor BI (SR-BI) mediates free cholesterol flux independently of HDL tethering to the cell surface. Journal of Lipid Research 1999, 40:575-580.
17. Dietschy J.M., Turley S.D. Cholesterol metabolism in the brain. Current Opinion in Lipidology 2001, 12:105-112.
18. Engelhart M.J., Geerlings M.I., Meijer J., Kiliaan A., Ruitenberg A., van Swieten J.C., Stijnen T., Hofman A., Witteman J.C., Breteler M.M. Inflammatory proteins in plasma and the risk of dementia: the rotterdam study. Archives of Neurology 2004, 61:668-672.
19. Esteve E., Ricart W., Fernandez-Real J.M. Dyslipidemia and inflammation: an evolutionary conserved mechanism. Clinical Nutrition 2005, 24:16-31.
20. Favari E., Lee M., Calabresi L., Franceschini G., Zimetti F., Bernini F., Kovanen P.T. Depletion of pre-beta-high density lipoprotein by human chymase impairs ATP-binding cassette transporter A1- but not scavenger receptor class B type I-mediated lipid efflux to high density lipoprotein. The Journal of Biological Chemistry 2004, 279:9930-9936.
21. Frisardi V., Panza F., Solfrizzi V., Seripa D., Pilotto A. Plasma lipid disturbances and cognitive decline. Journal of the American Geriatrics Society 2010, 58:2429-2430.
22. Gu F., Jones M.K., Chen J., Patterson J.C., Catte A., Jerome W.G., Li L., Segrest J.P. Structures of discoidal high density lipoproteins: a combined computational-experimental approach. The Journal of Biological Chemistry 2010, 285:4652-4665.
23. Haidar B., Denis M., Krimbou L., Marcil M., Genest J. cAMP induces ABCA1 phosphorylation activity and promotes cholesterol efflux from fibroblasts. Journal of Lipid Research 2002, 43:2087-2094.
24. Hajj Hassan H., Blain S., Boucher B., Denis M., Krimbou L., Genest J. Structural modification of plasma HDL by phospholipids promotes efficient ABCA1-mediated cholesterol release. Journal of Lipid Research 2005, 46:1457-1465.
25. Hartmann T. Cholesterol, A beta and Alzheimer's disease. Trends in Neurosciences 2001, 24:S45-S48.
26. Huang Y. Molecular and cellular mechanisms of apolipoprotein E4 neurotoxicity and potential therapeutic strategies. Current Opinion in Drug Discovery & Development 2006, 9:627-641.
27. Irizarry M.C., Deng A., Lleo A., Berezovska O., Von Arnim C.A., Martin-Rehrmann M., Manelli A., LaDu M.J., Hyman B.T., Rebeck G.W. Apolipoprotein E modulates gamma-secretase cleavage of the amyloid precursor protein. Journal of Neurochemistry 2004, 90:1132-1143.
28. Kalvodova L., Kahya N., Schwille P., Ehehalt R., Verkade P., Drechsel D., Simons K. Lipids as modulators of proteolytic activity of BACE: involvement of cholesterol, glycosphingolipids, and anionic phospholipids in vitro. The Journal of Biological Chemistry 2005, 280:36815-36823.
29. Khalil A., Fortin J.P., LeHoux J.G., Fulop T. Age-related decrease of dehydroepiandrosterone concentrations in low density lipoproteins and its role in the susceptibility of low density lipoproteins to lipid peroxidation. Journal of Lipid Research 2000, 41:1552-1561.
30. Khalil A., Jay-Gerin J.P., Fulop T. Age-related increased susceptibility of high-density lipoproteins (HDL) to in vitro oxidation induced by gamma-radiolysis of water. FEBS Letters 1998, 435:153-158.
31. Koukos G., Chroni A., Duka A., Kardassis D., Zannis V.I. LCAT can rescue the abnormal phenotype produced by the natural ApoA-I mutations (Leu141Arg)Pisa and (Leu159Arg)FIN. Biochemistry 2007, 46:10713-10721.
32. Laurin D., Masaki K.H., White L.R., Launer L.J. Ankle-to-brachial index and dementia: the Honolulu-Asia Aging Study. Circulation 2007, 116:2269-2274.
33. Lidington E.A., Moyes D.L., McCormack A.M., Rose M.L. A comparison of primary endothelial cells and endothelial cell lines for studies of immune interactions. Transplant Immunology 1999, 7:239-246.
34. Ligthart G.J., Corberand J.X., Fournier C., Galanaud P., Hijmans W., Kennes B., Muller-Hermelink H.K., Steinmann G.G. Admission criteria for immunogerontological studies in man: the SENIEUR protocol. Mechanisms of Ageing and Development 1984, 28:47-55.
35. Lutjohann D., Breuer O., Ahlborg G., Nennesmo I., Siden A., Diczfalusy U., Bjorkhem I. Cholesterol homeostasis in human brain: evidence for an age-dependent flux of 24S-hydroxycholesterol from the brain into the circulation. Proceedings of the National Academy of Sciences of the United States of America 1996, 93:9799-9804.
36. Marcil M., Yu L., Krimbou L., Boucher B., Oram J.F., Cohn J.S., Genest J. Cellular cholesterol transport and efflux in fibroblasts are abnormal in subjects with familial HDL deficiency. Arteriosclerosis, Thrombosis, and Vascular Biology 1999, 19:159-169.
37. McGrowder D., Riley C., Morrison E.Y., Gordon L. The role of high-density lipoproteins in reducing the risk of vascular diseases, neurogenerative disorders, and cancer. Cholesterol 2011, 2011:496925.
38. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
39. Mielke M.M., Zandi P.P., Shao H., Waern M., Ostling S., Guo X., Bjorkelund C., Lissner L., Skoog I., Gustafson D.R. The 32-year relationship between cholesterol and dementia from midlife to late life. Neurology 2010, 75:1888-1895.
40. Navab M., Anantharamaiah G.M., Reddy S.T., Van Lenten B.J., Ansell B.J., Fogelman A.M. Mechanisms of disease: proatherogenic HDL - an evolving field. Nature Clinical Practice. Endocrinology & Metabolism 2006, 2:504-511.
41. Navab M., Ananthramaiah G.M., Reddy S.T., Van Lenten B.J., Ansell B.J., Hama S., Hough G., Bachini E., Grijalva V.R., Wagner A.C., Shaposhnik Z., Fogelman A.M. The double jeopardy of HDL. Annals of Medicine 2005, 37:173-178.
42. Newman A.B., Fitzpatrick A.L., Lopez O., Jackson S., Lyketsos C., Jagust W., Ives D., Dekosky S.T., Kuller L.H. Dementia and Alzheimer's disease incidence in relationship to cardiovascular disease in the Cardiovascular Health Study cohort. Journal of the American Geriatrics Society 2005, 53:1101-1107.
43. Nunomura A., Perry G., Aliev G., Hirai K., Takeda A., Balraj E.K., Jones P.K., Ghanbari H., Wataya T., Shimohama S., Chiba S., Atwood C.S., Petersen R.B., Smith M.A. Oxidative damage is the earliest event in Alzheimer disease. Journal of Neuropathology and Experimental Neurology 2001, 60:759-767.
44. Panza F., Solfrizzi V., D'Introno A., Colacicco A.M., Santamato A., Seripa D., Pilotto A., Capurso A., Capurso C. Higher total cholesterol, cognitive decline, and dementia. Neurobiology of Aging 2009, 30:546-548.
45. Pfrieger F.W. Cholesterol homeostasis and function in neurons of the central nervous system. Cellular and Molecular Life Sciences: CMLS 2003, 60:1158-1171.
46. Puglielli L., Friedlich A.L., Setchell K.D., Nagano S., Opazo C., Cherny R.A., Barnham K.J., Wade J.D., Melov S., Kovacs D.M., Bush A.I. Alzheimer disease beta-amyloid activity mimics cholesterol oxidase. The Journal of Clinical Investigation 2005, 115:2556-2563.
47. Querfurth H.W., LaFerla F.M. Alzheimer's disease. The New England Journal of Medicine 2010, 362:329-344.
48. Refolo L.M., Malester B., LaFrancois J., Bryant-Thomas T., Wang R., Tint G.S., Sambamurti K., Duff K., Pappolla M.A. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiology of Disease 2000, 7:321-331.
49. Refolo L.M., Pappolla M.A., LaFrancois J., Malester B., Schmidt S.D., Thomas-Bryant T., Tint G.S., Wang R., Mercken M., Petanceska S.S., Duff K.E. A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiology of Disease 2001, 8:890-899.
50. Reitz C., Tang M.X., Schupf N., Manly J.J., Mayeux R., Luchsinger J.A. Association of higher levels of high-density lipoprotein cholesterol in elderly individuals and lower risk of late-onset Alzheimer disease. Archives of Neurology 2010, 67:1491-1497.
51. Sammalkorpi K., Valtonen V., Kerttula Y., Nikkila E., Taskinen M.R. Changes in serum lipoprotein pattern induced by acute infections. Metabolism: Clinical and Experimental 1988, 37:859-865.
52. Sattler W., Mohr D., Stocker R. Rapid isolation of lipoproteins and assessment of their peroxidation by high-performance liquid chromatography postcolumn chemiluminescence. Methods in Enzymology 1994, 233:469-489.
53. Schneider J.A., Wilson R.S., Bienias J.L., Evans D.A., Bennett D.A. Cerebral infarctions and the likelihood of dementia from Alzheimer disease pathology. Neurology 2004, 62:1148-1155.
54. Schonknecht P., Lutjohann D., Pantel J., Bardenheuer H., Hartmann T., von Bergmann K., Beyreuther K., Schroder J. Cerebrospinal fluid 24S-hydroxycholesterol is increased in patients with Alzheimer's disease compared to healthy controls. Neuroscience Letters 2002, 324:83-85.
55. Selkoe D.J. The molecular pathology of Alzheimer's disease. Neuron 1991, 6:487-498.
56. Simons M., Keller P., De Strooper B., Beyreuther K., Dotti C.G., Simons K. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proceedings of the National Academy of Sciences of the United States of America 1998, 95:6460-6464.
57. Singh-Manoux A., Gimeno D., Kivimaki M., Brunner E., Marmot M.G. Low HDL cholesterol is a risk factor for deficit and decline in memory in midlife: the Whitehall II study. Arteriosclerosis, Thrombosis, and Vascular Biology 2008, 28:1556-1562.
58. Smith J.D. Insight into ABCG1-mediated cholesterol efflux. Arteriosclerosis, Thrombosis, and Vascular Biology 2006, 26:1198-1200.
59. Tan Z.S., Beiser A.S., Vasan R.S., Roubenoff R., Dinarello C.A., Harris T.B., Benjamin E.J., Au R., Kiel D.P., Wolf P.A., Seshadri S. Inflammatory markers and the risk of Alzheimer disease: the Framingham Study. Neurology 2007, 68:1902-1908.
60. Tansley G.H., Burgess B.L., Bryan M.T., Su Y., Hirsch-Reinshagen V., Pearce J., Chan J.Y., Wilkinson A., Evans J., Naus K.E., McIsaac S., Bromley K., Song W., Yang H.C., Wang N., DeMattos R.B., Wellington C.L. The cholesterol transporter ABCG1 modulates the subcellular distribution and proteolytic processing of beta-amyloid precursor protein. Journal of Lipid Research 2007, 48:1022-1034.
61. Troncoso J.C., Zonderman A.B., Resnick S.M., Crain B., Pletnikova O., O'Brien R.J. Effect of infarcts on dementia in the Baltimore longitudinal study of aging. Annals of Neurology 2008, 64:168-176.
62. Tschape J.A., Hartmann T. Therapeutic perspectives in Alzheimer's disease. Recent Patents on CNS Drug Discovery 2006, 1:119-127.
63. Umeda T., Mori H., Zheng H., Tomiyama T. Regulation of cholesterol efflux by amyloid beta secretion. Journal of Neuroscience Research 2010, 88:1985-1994.
64. Van Lenten B.J., Hama S.Y., de Beer F.C., Stafforini D.M., McIntyre T.M., Prescott S.M., La Du B.N., Fogelman A.M., Navab M. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. The Journal of Clinical Investigation 1995, 96:2758-2767.
65. Wahrle S., Das P., Nyborg A.C., McLendon C., Shoji M., Kawarabayashi T., Younkin L.H., Younkin S.G., Golde T.E. Cholesterol-dependent gamma-secretase activity in buoyant cholesterol-rich membrane microdomains. Neurobiology of Disease 2002, 9:11-23.
66. Wang N., Silver D.L., Thiele C., Tall A.R. ATP-binding cassette transporter A1 (ABCA1) functions as a cholesterol efflux regulatory protein. The Journal of Biological Chemistry 2001, 276:23742-23747.
67. Weninger S.C., Yankner B.A. Inflammation and Alzheimer disease: the good, the bad, and the ugly. Nature Medicine 2001, 7:527-528.
68. Wolozin B. Cholesterol and the biology of Alzheimer's disease. Neuron 2004, 41:7-10.
69. Wolozin B. A fluid connection: cholesterol and Abeta. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:5371-5373.
70. Wolozin B., Kellman W., Ruosseau P., Celesia G.G., Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Archives of Neurology 2000, 57:1439-1443.
71. Xiong H., Callaghan D., Jones A., Walker D.G., Lue L.F., Beach T.G., Sue L.I., Woulfe J., Xu H., Stanimirovic D.B., Zhang W. Cholesterol retention in Alzheimer's brain is responsible for high beta- and gamma-secretase activities and Abeta production. Neurobiology of Disease 2008, 29:422-437.
72. Yancey P.G., Asztalos B.F., Stettler N., Piccoli D., Williams D.L., Connelly M.A., Rothblat G.H. SR-BI- and ABCA1-mediated cholesterol efflux to serum from patients with Alagille syndrome. Journal of Lipid Research 2004, 45:1724-1732.
73. Yancey P.G., Bortnick A.E., Kellner-Weibel G., de la Llera-Moya M., Phillips M.C., Rothblat G.H. Importance of different pathways of cellular cholesterol efflux. Arteriosclerosis, Thrombosis, and Vascular Biology 2003, 23:712-719.
74. Ye S., Huang Y., Mullendorff K., Dong L., Giedt G., Meng E.C., Cohen F.E., Kuntz I.D., Weisgraber K.H., Mahley R.W. Apolipoprotein (apo) E4 enhances amyloid beta peptide production in cultured neuronal cells: apoE structure as a potential therapeutic target. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:18700-18705.
75. Zannis V.I., Chroni A., Krieger M. Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL. Journal of Molecular Medicine 2006, 84:276-294.
76. Zuliani G., Cavalieri M., Galvani M., Volpato S., Cherubini A., Bandinelli S., Corsi A.M., Lauretani F., Guralnik J.M., Fellin R., Ferrucci L. Relationship between low levels of high-density lipoprotein cholesterol and dementia in the elderly. The InChianti study. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences 2010, 65:559-564.